Get the Stockscreener App
0.5632
2.05%
-0.0118
Enzo Biochem Inc stock is traded at $0.5632, with a volume of 45,789.
It is down -2.05% in the last 24 hours and down -20.15% over the past month.
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.
See More
Previous Close:
$0.575
Open:
$0.57
24h Volume:
45,789
Relative Volume:
0.29
Market Cap:
$30.04M
Revenue:
$30.31M
Net Income/Loss:
$-22.84M
P/E Ratio:
-1.2516
EPS:
-0.45
Net Cash Flow:
$-22.61M
1W Performance:
-7.05%
1M Performance:
-20.15%
6M Performance:
-47.36%
1Y Performance:
-55.65%
1-Day Range:
$0.5621
$0.575
1-Week Range:
$0.561
$0.6147
52-Week Range:
$0.561
$1.40
Enzo Biochem Inc Stock (ENZ) Company Profile
Name
Enzo Biochem Inc
Sector
Industry
Phone
(516) 755-5500
Address
60 EXECUTIVE BLVD, FARMINGDALE, NY
Compare ENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENZ
Enzo Biochem Inc
|
0.5631 | 30.04M | 30.31M | -22.84M | -22.61M | -0.45 |
|
TMO
Thermo Fisher Scientific Inc
|
568.24 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
206.88 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
145.19 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
457.80 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
207.19 | 36.97B | 15.32B | 1.41B | 1.96B | 7.62 |
Enzo Biochem Inc Stock (ENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-18-11 | Reiterated | Rodman & Renshaw | Mkt Outperform |
| Sep-23-09 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Sep-13-07 | Initiated | Lazard Capital | Buy |
Enzo Biochem Inc Stock (ENZ) Latest News
Neuroscience Antibodies and Assays Market to Grow by USD 2.20 Billion from 2024-2028, Rising Neurological Disorders Boost Growth, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ) - Defense World
Enzo Biochem stock hits 52-week low at $0.63 amid market challenges - Investing.com Nigeria
Enzo Biochem stock hits 52-week low at $0.63 amid market challenges By Investing.com - Investing.com South Africa
Enzo Biochem settles class action for $7.5 million - MSN
Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com - Defense World
Enzo Biochem settles class action for $7.5 million By Investing.com - Investing.com Australia
Enzo Biochem shareholders elect board, approve executive pay - Investing.com India
Enzo Biochem shareholders elect board, approve executive pay By Investing.com - Investing.com UK
Enzo Biochem's Strategy to Resolve NYSE Compliance IssuesLife Science Industry News - Zenopa
Enzo Biochem Agrees to Settlement in Class Action Suit Related to Ransomware Attack - Defense World
Enzo Biochem to Pay $7.5 Million to Settle Suit Over 2023 Breach - Bloomberg Law
Enzo Biochem Receives Notice from NYSE Regarding Listing ComplianceFarmingdale, NY – Enzo Biochem, Inc. (NYSE: ENZ) recently disclosed that it received a notice from the New York Stock Exchange (NYSE) indicating non-compliance with certain listing - Defense World
Enzo Biochem faces NYSE compliance challenges By Investing.com - Investing.com Canada
Enzo Biochem faces NYSE compliance challenges - Investing.com
Enzo Biochem Faces NYSE Compliance Challenges - TipRanks
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules - The Manila Times
Enzo Biochem Receives NYSE Non-Compliance Notice Over Market Cap and Share Price Issues - StockTitan
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges - MSN
Enzo Biochem (NYSE:ENZ) versus Grail (NASDAQ:GRAL) Financial Review - Defense World
StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ) - Defense World
Enzo Biochem stock hits 52-week low at $0.68 amid challenges - Investing.com Nigeria
Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com - Defense World
Enzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.com - Defense World
Enzo Biochem (ENZ) Stock Surges 5.19% Amid Market Activity - GuruFocus.com
Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk - Simply Wall St
Enzo Biochem First Quarter 2025 Earnings: US$0.059 loss per share (vs US$0.11 loss in 1Q 2024) - Yahoo Finance
Enzo Biochem stock hits 52-week low at $0.92 amid challenges - Investing.com
Enzo Biochem: Fiscal Q1 Earnings Snapshot - Midland Daily News
Enzo Biochem (NYSE:ENZ) Now Covered by Analysts at StockNews.com - MarketBeat
Enzo Biochem, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2024 - Marketscreener.com
Enzo Biochem Reports Narrowed Loss Amid Revenue Decline - TipRanks
ENZEnzo Biochem, Inc. Latest Stock News & Market Updates - StockTitan
Enzo Biochem (NYSE:ENZ) Announces Quarterly Earnings Results - MarketBeat
Enzo Biochem Inc Stock (ENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.57%
1.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):